Quantcast

Latest DCIS Stories

2014-06-01 08:20:43

New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX(®)( )in pre-invasive and invasive breast cancer and colon...

2014-05-06 16:32:54

13% Increase in Test Volume and 7% Increase in Product Revenue Compared to Prior Year REDWOOD CITY, Calif., May 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2014. Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO Product revenue was $67.0 million in the first quarter of 2014, compared with $62.7 million for the first quarter of 2013, an increase of 7 percent. Total revenue for...

2014-05-05 08:28:31

New Data Include Results on Oncotype DX's Prognosis of Late Recurrence in Invasive Breast Cancer and Clinical Utility in Ductal Carcinoma In Situ (DCIS) REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place...

2014-04-04 23:34:52

Cianna Medical, Inc.: Strut-based breast cancer radiation treatment could expand options for DCIS patients. Aliso Viejo, Calif. (PRWEB) April 03, 2014 Cianna Medical, Inc., a women’s health company, today announced the results of a retrospective study of breast cancer patients with ductal carcinoma in situ (DCIS) treated with SAVI® breast brachytherapy. Researchers reported excellent local control, with recurrence rates that appear to be equivalent to those expected for whole...

2013-10-11 23:19:21

Ductal carcinoma in situ (DCIS), a noninvasive breast cancer that some doctors are now arguing is over-treated, needs to be evaluated according to each woman’s risk, and more research is needed to better evaluate that risk, two Allegheny Health Network oncologists write in the Journal of the National Cancer Institute. DCIS represents up to 25% of new breast cancer diagnosis. Pittsburgh, PA (PRWEB) October 11, 2013 Ductal carcinoma in situ (DCIS), a noninvasive breast cancer that some...

2013-09-18 15:45:20

Results of EORTC trial 10853 appearing in the Journal of Clinical Oncology show that breast conserving treatment combined with radiotherapy reduces the risk of local recurrence in women with ductal carcinoma in situ (DCIS). The incidence of DCIS has been increasing in the past decades, and this has been attributed to increased detection through breast cancer screening using mammograms. In the EORTC study, adjuvant radiotherapy after local excision reduced the incidence of both in situ and...

2012-11-29 14:32:03

The combined loss of two tumor suppressor genes, retinoblastoma (RB) and phosphatase and tensin homolog (PTEN) was shown to be strongly associated with progression of DCIS to invasive breast cancer, according to a study published November 28 in the Journal of the National Cancer Institute. Ductal carcinoma in situ (DCIS) is a breast cancer precursor lesion for which there are no established markers defining risk of progression to invasive breast cancer. As a result, the majority of...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related